|
|
 | | | |
- close
- close
- close
- close
| |||||||||
These excerpts taken from the MEMY 10-K filed Mar 28, 2008. PDE10
Inhibitor Program
PDE10 is an enzyme that has been shown to be present at high
levels in neurons in areas of the brain that are closely
associated with many neurological and psychiatric disorders.
PDE10 degrades the intracellular signaling molecules cAMP and
cGMP, molecules that are responsible for improving the function
of many different cells in the body, including neurons. By
inhibiting PDE10, levels of cAMP and cGMP are increased within
neurons and the ability of these neurons to function properly is
thereby improved. We believe that PDE10 inhibitors may be useful
in treating a range of neurological and psychiatric disorders.
Under our collaboration agreement with Amgen for the development
of PDE10 inhibitors, which we refer to as our 2005 Amgen PDE10
Inhibitor Agreement, Amgen has an exclusive license to our PDE10
inhibitors.
PDE10 Inhibitor Program PDE10 is an enzyme that has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. PDE10 degrades the intracellular signaling molecules cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved. We believe that PDE10 inhibitors may be useful in treating a range of neurological and psychiatric disorders. Under our collaboration agreement with Amgen for the development of PDE10 inhibitors, which we refer to as our 2005 Amgen PDE10 Inhibitor Agreement, Amgen has an exclusive license to our PDE10 inhibitors. This excerpt taken from the MEMY 10-K filed Apr 2, 2007. PDE10 Inhibitor Program PDE10 is an enzyme that has been shown to be present at high levels in neurons in areas of the brain that are closely associated with many neurological and psychiatric disorders. PDE10 degrades the intracellular signaling molecules cAMP and cGMP, molecules that are responsible for improving the function of many different cells in the body, including neurons. By inhibiting PDE10, levels of cAMP and cGMP are increased within neurons and the ability of these neurons to function properly is thereby improved. We believe that PDE10 inhibitors may be useful in treating a range of neurological and psychiatric disorders. Under our 2005 Amgen Agreement, Amgen has an exclusive license to any PDE10 inhibitors that we develop. | EXCERPTS ON THIS PAGE:
|
| |||||||
